Diagnosis, Pathogenesis, Treatment and Prognosis of Glioblastoma
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 134
Special Issue Editor
Interests: Neuro-oncologia, Cirurgia de tumores cerebrais com o doente acordado e mapeamento cerebral, Cirurgia de tumores cerebrais com imunofluorescência, Cirurgia de gliomas de baixo grau, Cirurgia da epilepsia, Cirurgia Intracraniana, Patologia da Coluna Vertebral.
Special Issue Information
Dear Colleagues,
Are the genetic changes already adequately known to determine the biological behavior of glioblastomas? Will there be immunotherapy and effective directed treatments for glioblastomas? What is the best treatment for elderly patients and for patients with multicentric lesions? What is the role of reirradiation? What is the experience so far with LITT and TTF?
Although there have been recent advances in molecular characterization and treatments, the prognostic remains dismissive, with most patients dying within 15–18 months. In the USA, the 5-year survival rate has been reported as 6.8%.
Despite the longer genetic and molecular assessment of glioblastoma, the standard treatment is still a combination of surgery, radiotherapy and chemotherapy; thus, significant ongoing challenges remain for the treatment.
The relationship of genetic and molecular changes with image findings may allow different diagnostic approaches.
Understanding glioblastoma and its pathogenesis is critical for researching new forms of treatment as well understanding its resistance mechanisms and escape from immune surveillance.
In addition to immunotherapy and target therapies, non-pharmacological options such as TTFs and LITT have emerged as viable treatment options, although with currently uncertain results.
Here, we will try to provide answers to some of these questions, and we will certainly raise other questions that will remain unanswered.
Prof. Dr. Paulo Linhares
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioblastoma
- immunotherapy
- molecular subtype
- radiotherapy
- molecular therapy
- emerging treatment
- drug resistance
- MRI
- immune surveillance
